-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis
-
-
-
-
-
-
-
Sensei Biotherapeutics (SNSE) Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
-
-
-
-
-
-
-
Natera (NTRA) to Present New MRD Data in Multiple Tumor Types
-
-
-
-
-
-
-
BioVie Inc. (BIVI) Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
-
-
-
-
-
-
-
Rezolute Inc. (RZLT) Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402
-
-
-
-
-
-
-
Palisade Bio Inc. (PALI) Reports PALI-2108 Demonstrated Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb (BMY) Received Updated Action Date from FDA for Subcutaneous Nivolumab Co-Formulated with ENHANZE
-
67,154 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.